Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
October 18, 2004
- Domestic SMO Market Showing Strong Growth: Survey
October 18, 2004
- Application of Nasal Endoscopy Increasing: Fujinon Toshiba
October 18, 2004
- Alfresa HD to Focus on Market Share in Tokai, Kansai Regions
October 18, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 18, 2004
- BUSINESS NEWS IN BRIEF
October 18, 2004
- PRESS SEMINAR
October 18, 2004
- 11 Drugs Including Trisrenox Inj. Approved
October 18, 2004
- Pemetrexed Approved in EU for Two Cancer Indications: Eli Lilly
October 18, 2004
- WORLD NEWS IN BRIEF
October 11, 2004
- Major Hospitals Required to Report Serious Medical Accidents
October 11, 2004
- Camurus Hopes to License Its Innovative DDS Technology in Japan: Dr Westrin
October 11, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 11, 2004
- IFPW General Membership Meeting
October 11, 2004
- In-house Product Launchings Expected from FY2008: Nippon Kayaku
October 11, 2004
- NHI Pricing Should Be Based on Market Price Principle: Prof. Tsutsumi
October 11, 2004
- Pharmacoeconomic Evaluation of Long-term Effects on Health Recommended
October 11, 2004
- BUSINESS NEWS IN BRIEF
October 11, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 11, 2004
- Annual Business Results
October 11, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…